Nervous System News and Research

Latest Nervous System News and Research

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

The sugar-alcohol compound mannitol improved the therapeutic effectiveness of human umbilical cord blood cells injected into neonatal rat models of cerebral palsy, reports a new international study led by the University of South Florida. The mannitol opened the blood-brain barrier by temporarily shrinking the tight endothelial cells that make up the barrier.

2 Jun 2010

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

The majority of Australians (58%) are worried about their brain health and the threat of age-related degenerative brain disease, according to a new survey. The national survey was commissioned by leading medical research institute Neuroscience Research Australia and polled 1000 Australians aged 18 to over 75.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

When we get angry, the heart rate, arterial tension and testosterone production increases, cortisol (the stress hormone) decreases, and the left hemisphere of the brain becomes more stimulated. This is indicated by a new investigation lead by scientists from the University of Valencia that analyses the changes in the brain's cardiovascular, hormonal and asymmetric activation response when we get angry.

31 May 2010

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.

31 May 2010

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Researchers in the University of Alberta's Faculty of Rehabilitation Medicine have made an important discovery that could lead to more effective treatments for spinal-cord injuries. Karim Fouad and David Bennett have identified one of the body's natural self-repair mechanisms that kick in after injury.

31 May 2010

Adenosine plays major role in parlaying effects of acupuncture

Scientists have taken another important step toward understanding just how sticking needles into the body can ease pain.

31 May 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 –30 in Athens, Greece.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

New book summarizes current state of research on NF-κB

NF-κB is a critical signaling molecule in the immune system that regulates cell survival and cell death, lymphocyte responses, and inflammation. Acting as a transcription factor that can receive several inputs, it coordinates distinct gene expression programs in response to a wide variety of stimuli.

26 May 2010

UCSF scientists discover new stem cell in developing human brain

UCSF scientists have discovered a new stem cell in the developing human brain. The cell produces nerve cells that help form the neocortex - the site of higher cognitive function -- and likely accounts for the dramatic expansion of the region in the lineages that lead to man, the researchers say.

26 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

26 May 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

25 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Nervous System News and Research

Latest Nervous System News and Research

UCI study provides blueprint for enhanced treatment of inflammatory diseases

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Adenosine plays major role in parlaying effects of acupuncture

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Modified measles virus may hold potential for treatment of medulloblastoma

New book summarizes current state of research on NF-κB

UCSF scientists discover new stem cell in developing human brain

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in